The current study created a controlled-release formulation of Mesna to keep the drug at therapeutic levels for longer than ten hours. Eudragit L 100, Chitosan, HPMC K4M. The dose of mesna was set at 100 mg. The tablet's total weight was calculated to be 100 mg. Polymers were employed in concentrations of 50 mg, 100 mg, and 150 mg. Every formulation passed several physicochemical evaluation criteria and was determined to be within tolerances. However, it was clear from the dissolving trials that the formulation (F6) had a better and more desirable drug release pattern, achieving 96.47% in 10 hours. As a controlled release substance, it contains the naturally occurring polymer Mesna. The release kinetics mechanism was in zero order. The optimal formulation was used again for reproducibility, and conformance was tested in all quality control procedures. It was discovered that the outcomes were very impossible for one another. The optimized formula will be used for formulation development and other studies, such as bio-equivalency research, to ensure a successful product launch.
{"title":"Design and characterization of controlled release formulation of Mesna by using different polymers","authors":"Padhy Aniket, Gopi G, P. Pk","doi":"10.26452/fjphs.v4i3.643","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.643","url":null,"abstract":"The current study created a controlled-release formulation of Mesna to keep the drug at therapeutic levels for longer than ten hours. Eudragit L 100, Chitosan, HPMC K4M. The dose of mesna was set at 100 mg. The tablet's total weight was calculated to be 100 mg. Polymers were employed in concentrations of 50 mg, 100 mg, and 150 mg. Every formulation passed several physicochemical evaluation criteria and was determined to be within tolerances. However, it was clear from the dissolving trials that the formulation (F6) had a better and more desirable drug release pattern, achieving 96.47% in 10 hours. As a controlled release substance, it contains the naturally occurring polymer Mesna. The release kinetics mechanism was in zero order. The optimal formulation was used again for reproducibility, and conformance was tested in all quality control procedures. It was discovered that the outcomes were very impossible for one another. The optimized formula will be used for formulation development and other studies, such as bio-equivalency research, to ensure a successful product launch.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"6 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141802015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The research aims to formulate and evaluate the Metoprolol succinate buccal tablets in hypertension treatment. The Fourier transform infrared (FTIR) results depict no incompatibility between the drug and excipients. The study results of pre-compression parameters have excellent flow qualities and compressibility. The post-compression parameters show that the results are within the specified standard deviations. The swelling index reveals that the formulation F6 shows that the complete drug was released and the tablet integrity was maintained during the expected duration. Formulation F6 chitosan and Carbopol 934 were used in a ratio of 1:1, resulting in the release of the drug up to the 10th hour and completely. Therefore, formulation F6 was optimized and compared with the marketed product. Formulation F6 exhibited better drug release performance than the marketed product.
{"title":"Formulation and evaluation of Metoprolol succinate buccal tablets in hypertension treatment","authors":"Kishore Bandarapalle, Rajasekhar Kk, Teja Sri Kamasani, Sangeetha Mohanrao, Neeraja Boyalapalli, Likhitha Chejarla, Bhargavi Cy, Chaitanya Krishna","doi":"10.26452/fjphs.v4i3.636","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.636","url":null,"abstract":"The research aims to formulate and evaluate the Metoprolol succinate buccal tablets in hypertension treatment. The Fourier transform infrared (FTIR) results depict no incompatibility between the drug and excipients. The study results of pre-compression parameters have excellent flow qualities and compressibility. The post-compression parameters show that the results are within the specified standard deviations. The swelling index reveals that the formulation F6 shows that the complete drug was released and the tablet integrity was maintained during the expected duration. Formulation F6 chitosan and Carbopol 934 were used in a ratio of 1:1, resulting in the release of the drug up to the 10th hour and completely. Therefore, formulation F6 was optimized and compared with the marketed product. Formulation F6 exhibited better drug release performance than the marketed product.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"37 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141816775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Harika Sirivella, Lavanya Agamudi, Sarah Sujitha Y
The pharmaceutical industry faces exceptionally high R&D costs, with the US research-based sector investing about 17% of sales into R&D. The cost of bringing a new compound to market was estimated at $802 million in 2001, up from $138 million in the 1970s and $318 million in the 1990s, necessitating stringent regulations. This study aims to determine the role and impact of India's pharmaceutical industry and its regulatory compliance. Personnel from organizations established between 1884 and 2004, with turnovers ranging from Rs. 25 crore (US $5.3 million) to Rs. 5500 crore (US $1.2 billion), were surveyed. Out of 150 companies approached, 73 responded, with 70 complete responses analyzed. Ongoing interactions with regulatory agencies helped companies better understand the regulatory system. Three key areas emerged as priorities: awareness of intellectual property rights (IPR) and patents, fostering a suitable environment for research and development, and implementing Good Manufacturing Practices (GMP), considered more critical than price control. The findings underscore the importance of regulatory compliance in promoting innovation and maintaining quality within the pharmaceutical industry, ensuring its competitiveness and ability to meet global standards.
{"title":"Deciphering the role and impact of India's pharmaceutical industries and its regulatory compliance","authors":"Harika Sirivella, Lavanya Agamudi, Sarah Sujitha Y","doi":"10.26452/fjphs.v4i3.634","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.634","url":null,"abstract":"The pharmaceutical industry faces exceptionally high R&D costs, with the US research-based sector investing about 17% of sales into R&D. The cost of bringing a new compound to market was estimated at $802 million in 2001, up from $138 million in the 1970s and $318 million in the 1990s, necessitating stringent regulations. This study aims to determine the role and impact of India's pharmaceutical industry and its regulatory compliance. Personnel from organizations established between 1884 and 2004, with turnovers ranging from Rs. 25 crore (US $5.3 million) to Rs. 5500 crore (US $1.2 billion), were surveyed. Out of 150 companies approached, 73 responded, with 70 complete responses analyzed. Ongoing interactions with regulatory agencies helped companies better understand the regulatory system. Three key areas emerged as priorities: awareness of intellectual property rights (IPR) and patents, fostering a suitable environment for research and development, and implementing Good Manufacturing Practices (GMP), considered more critical than price control. The findings underscore the importance of regulatory compliance in promoting innovation and maintaining quality within the pharmaceutical industry, ensuring its competitiveness and ability to meet global standards.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"9 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141815984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Among innovative drug delivery methods, buccal mucoadhesive systems have been attracting much interest recently because of their capacity to stick to the oral mucosa, stay there, and gradually release their drug content. By improving medication absorption through the oral mucosa and reducing the hepatic first-pass impact, buccal mucoadhesive films can increase the drug's bioavailability and enhance its therapeutic effect. The current study aimed to synthesize the medicine as a buccal bioadhesive film, which reduces the frequency of dosage form administration by releasing the drug at a sufficient concentration over time. Because this formulation is simple to administer and requires no water to swallow, improved patient compliance is one of its benefits. Dissolving profile as investigated in USP dissolving apparatus type 1 using saliva at pH 6.8. The impact of factors such as polymer type, concentration, and release profile of Amoxapine was investigated. The formulation was optimized Based on several evaluation criteria, including drug content and in-vitro drug release. Formulation F6 successfully releases the drug in 7 hours. The stability studies followed ICH recommendations, and the results showed that the optimized formulation was stable. The IR spectra demonstrated the stable qualities of Amoxapine in a mixture of polymers utilized and revealed the absence of interaction between the drug and the selected polymer.
{"title":"Formulation and evaluation of amoxapine mucoadhesive buccal films","authors":"Mahaboob Ali Sk., S. Kv, Gautham Chakra R","doi":"10.26452/fjphs.v4i3.629","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.629","url":null,"abstract":"Among innovative drug delivery methods, buccal mucoadhesive systems have been attracting much interest recently because of their capacity to stick to the oral mucosa, stay there, and gradually release their drug content. By improving medication absorption through the oral mucosa and reducing the hepatic first-pass impact, buccal mucoadhesive films can increase the drug's bioavailability and enhance its therapeutic effect. The current study aimed to synthesize the medicine as a buccal bioadhesive film, which reduces the frequency of dosage form administration by releasing the drug at a sufficient concentration over time. Because this formulation is simple to administer and requires no water to swallow, improved patient compliance is one of its benefits. Dissolving profile as investigated in USP dissolving apparatus type 1 using saliva at pH 6.8. The impact of factors such as polymer type, concentration, and release profile of Amoxapine was investigated. The formulation was optimized Based on several evaluation criteria, including drug content and in-vitro drug release. Formulation F6 successfully releases the drug in 7 hours. The stability studies followed ICH recommendations, and the results showed that the optimized formulation was stable. The IR spectra demonstrated the stable qualities of Amoxapine in a mixture of polymers utilized and revealed the absence of interaction between the drug and the selected polymer.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"117 44","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141666659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study aimed to formulate a gel for hydroquinone dermal therapy using liposomes to maintain the active agents' concentration in the skin's deepest layers. Cholesterol was incorporated to enhance the liposome's bilayer characteristics, increasing microviscosity, membrane stability, and blister rigidity. Various methods for liposome preparation exist, but the film hydration method, being the most common, was utilized here. Results for formulation HL6, which had lower levels of Lecithin Cholesterol and rotation speed, revealed a vesicle size of 180.4 nm, a Zeta potential of -37.5 mV, and an entrapment efficiency of 69.10±1.52%. In-vitro drug release data for formulations F1, F2, and F3 within 30 minutes showed hydroquinone release rates of 97.75±0.28%, 98.92±0.56%, and 94.45±0.36%, respectively. The order of drug release was F2 > F1 > F3, with F2 demonstrating the maximum release rate. The study concludes that liposomal gel is an effective transdermal drug delivery system for therapeutic molecules. Lipid vesicles, such as liposomes, are among the best mechanisms for delivering medications to their intended locations while minimizing their dissemination to non-target tissues. This liposomal gel-based formulation shows significant potential for effectively treating acne by maintaining high concentrations of active agents in the skin's deepest layers and ensuring a controlled and sustained drug release.
{"title":"Fabrication and characterization of hydroquinone in liposomal gel for transdermal drug delivery","authors":"V. Penabaka, Chandrika Jorepalli, Harika Kandala, Nichitha Lakku, Nikhil Orugunta, Thulasi Thandra, Prapurnachandra Yadala","doi":"10.26452/fjphs.v4i3.628","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.628","url":null,"abstract":"This study aimed to formulate a gel for hydroquinone dermal therapy using liposomes to maintain the active agents' concentration in the skin's deepest layers. Cholesterol was incorporated to enhance the liposome's bilayer characteristics, increasing microviscosity, membrane stability, and blister rigidity. Various methods for liposome preparation exist, but the film hydration method, being the most common, was utilized here. Results for formulation HL6, which had lower levels of Lecithin Cholesterol and rotation speed, revealed a vesicle size of 180.4 nm, a Zeta potential of -37.5 mV, and an entrapment efficiency of 69.10±1.52%. In-vitro drug release data for formulations F1, F2, and F3 within 30 minutes showed hydroquinone release rates of 97.75±0.28%, 98.92±0.56%, and 94.45±0.36%, respectively. The order of drug release was F2 > F1 > F3, with F2 demonstrating the maximum release rate. The study concludes that liposomal gel is an effective transdermal drug delivery system for therapeutic molecules. Lipid vesicles, such as liposomes, are among the best mechanisms for delivering medications to their intended locations while minimizing their dissemination to non-target tissues. This liposomal gel-based formulation shows significant potential for effectively treating acne by maintaining high concentrations of active agents in the skin's deepest layers and ensuring a controlled and sustained drug release.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"3 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141669947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The treatment of chronic diseases poses significant challenges to healthcare systems worldwide. While conventional medical approaches have made substantial progress, alternative medicines have gained recognition for their potential to complement or even substitute conventional treatments. This comprehensive review examines the role of alternative medications in chronic disease management, encompassing a wide range of modalities, from herbal remedies and acupuncture to mind-body therapies and chiropractic care. We explore the efficacy and safety of alternative treatments, mechanisms of action, patient perspectives, regulatory and ethical considerations, cost-effectiveness, and the potential for integration with conventional medicine. Drawing upon clinical studies, patient testimonials, and scholarly sources, this review highlights alternative medicine's diverse and evolving landscape, its significance in improving patient outcomes, and the challenges that must be addressed. We offer recommendations for patients, healthcare providers, and policymakers on integrating and responsible use of alternative medicines in chronic disease management.
{"title":"Significance of Alternative Medicines in Treatment of Chronic Diseases: A Comprehensive Review","authors":"Afsar Shaik, Fazeen Mohamed","doi":"10.26452/fjphs.v4i3.630","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.630","url":null,"abstract":"The treatment of chronic diseases poses significant challenges to healthcare systems worldwide. While conventional medical approaches have made substantial progress, alternative medicines have gained recognition for their potential to complement or even substitute conventional treatments. This comprehensive review examines the role of alternative medications in chronic disease management, encompassing a wide range of modalities, from herbal remedies and acupuncture to mind-body therapies and chiropractic care. We explore the efficacy and safety of alternative treatments, mechanisms of action, patient perspectives, regulatory and ethical considerations, cost-effectiveness, and the potential for integration with conventional medicine. Drawing upon clinical studies, patient testimonials, and scholarly sources, this review highlights alternative medicine's diverse and evolving landscape, its significance in improving patient outcomes, and the challenges that must be addressed. We offer recommendations for patients, healthcare providers, and policymakers on integrating and responsible use of alternative medicines in chronic disease management.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"113 26","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141667902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sujana A, Durga Prasad K, Sarada Mrinalini Talluri
Lercanidipine blocks the entry of extracellular calcium into vascular and cardiac muscle cells, preventing myocardial smooth muscle contraction due to decreased intracellular calcium. This results in the dilation of coronary and systemic arteries, reducing blood pressure. This study aimed to develop and evaluate lercanidipine controlled-release tablets for oral administration using polymers like HPMC K 100M, sodium alginate, and guar gum. Lercanidipine, polymers, and diluents were sieved and mixed for 10 minutes. Granules were formed using isopropyl alcohol, dried at 60°C for one hour, and sieved. The granules were lubricated with colloidal silicon dioxide (Aerosil-200) and magnesium stearate, blended for 5 minutes, and compressed using a rotary machine (average weight: 500 mg; hardness: 5-6 kg/cm²). Bulk and tapped densities were nearly identical for all formulations. Compressibility index and Hausner ratio ranged from ?18 to 1.09-1.21, indicating good flow properties. Tablet thickness ranged from 5.82 to 5.91 mm, hardness from 5.9 to 6.3 kg/cm², and friability was less than 1.0 %W/W. Drug content was between 98-102%. The controlled-release order from dissolution data was F9 > F7 > F8, showing optimal release with a combination of HPMC and two natural polymers.
{"title":"Controlled Release Lercanidipine Tablets: A Study on Formulation and Evaluation by Wet Granulation","authors":"Sujana A, Durga Prasad K, Sarada Mrinalini Talluri","doi":"10.26452/fjphs.v4i3.623","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.623","url":null,"abstract":"Lercanidipine blocks the entry of extracellular calcium into vascular and cardiac muscle cells, preventing myocardial smooth muscle contraction due to decreased intracellular calcium. This results in the dilation of coronary and systemic arteries, reducing blood pressure. This study aimed to develop and evaluate lercanidipine controlled-release tablets for oral administration using polymers like HPMC K 100M, sodium alginate, and guar gum. Lercanidipine, polymers, and diluents were sieved and mixed for 10 minutes. Granules were formed using isopropyl alcohol, dried at 60°C for one hour, and sieved. The granules were lubricated with colloidal silicon dioxide (Aerosil-200) and magnesium stearate, blended for 5 minutes, and compressed using a rotary machine (average weight: 500 mg; hardness: 5-6 kg/cm²). Bulk and tapped densities were nearly identical for all formulations. Compressibility index and Hausner ratio ranged from ?18 to 1.09-1.21, indicating good flow properties. Tablet thickness ranged from 5.82 to 5.91 mm, hardness from 5.9 to 6.3 kg/cm², and friability was less than 1.0 %W/W. Drug content was between 98-102%. The controlled-release order from dissolution data was F9 > F7 > F8, showing optimal release with a combination of HPMC and two natural polymers.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":" 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141675440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adrenoleukodystrophy (ALD) is a rare X-linked peroxisomal oxidation disease caused by mutations in ABCD1. It presents with various clinical manifestations, including cerebral ALD, myelopathy, and primary adrenal insufficiency. About 80% of ALD patients suffer from adrenal insufficiency, and cerebral ALD affects one-third of boys under twelve, progressing to total impairment and death without treatment. Hematopoietic stem cell transplantation (HSCT) is the only disease-modifying treatment for early-stage cerebral ALD, but it does not halt adrenal insufficiency progression and carries significant morbidity and mortality risks. A recent gene therapy clinical trial showed short-term MRI and neurological outcomes equivalent to past HSCT treatments without the adverse side effects. Additionally, over a dozen states have initiated newborn screening (NBS) for ALD, with the number expected to triple by 2020. Genetic testing of NBS-positive newborns has identified novel variations of unknown significance, raising questions about monitoring and treating preclinical or moderate adrenal insufficiency or cerebral involvement. This presents further opportunities for genetic characterization. The availability of matching donors, transplant centers, and specialists will impact prompt treatment for those diagnosed with ALD at birth. As NBS and gene therapy trials improve ALD's clinical management and prognosis, endocrine management of presymptomatic and subclinical adrenal insufficiency will become increasingly important.
{"title":"Adrenoleukodystrophy an Overview","authors":"Achala Kp, Niharika Kj, Shashank Kr, Prajnesh J Shetty","doi":"10.26452/fjphs.v4i3.625","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.625","url":null,"abstract":"Adrenoleukodystrophy (ALD) is a rare X-linked peroxisomal oxidation disease caused by mutations in ABCD1. It presents with various clinical manifestations, including cerebral ALD, myelopathy, and primary adrenal insufficiency. About 80% of ALD patients suffer from adrenal insufficiency, and cerebral ALD affects one-third of boys under twelve, progressing to total impairment and death without treatment. Hematopoietic stem cell transplantation (HSCT) is the only disease-modifying treatment for early-stage cerebral ALD, but it does not halt adrenal insufficiency progression and carries significant morbidity and mortality risks. A recent gene therapy clinical trial showed short-term MRI and neurological outcomes equivalent to past HSCT treatments without the adverse side effects. Additionally, over a dozen states have initiated newborn screening (NBS) for ALD, with the number expected to triple by 2020. Genetic testing of NBS-positive newborns has identified novel variations of unknown significance, raising questions about monitoring and treating preclinical or moderate adrenal insufficiency or cerebral involvement. This presents further opportunities for genetic characterization. The availability of matching donors, transplant centers, and specialists will impact prompt treatment for those diagnosed with ALD at birth. As NBS and gene therapy trials improve ALD's clinical management and prognosis, endocrine management of presymptomatic and subclinical adrenal insufficiency will become increasingly important.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":" 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141675928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diabetes mellitus, a modern civilization disease, is marked by chronic hyperglycemia and severe complications if untreated. Type II DM, a multifactorial form, accounts for 90% of global cases. Controlling postprandial glucose is vital for preventing complications, as elevated plasma glucose is influenced by ?-amylase and ?-glucosidases. Current enzyme inhibitors like Acarbose and voglibose cause gastrointestinal side effects. This study aimed to find natural source inhibitors with fewer adverse effects using in-vitro antidiabetic assays. Mespilus germanica L. leaf juice (20-100 ?g/ml) was tested against fungal ?-amylase and ?-glucosidases from albino rat intestines. The enzymes showed dose-dependent inhibition comparable to Acarbose. LJMG and Acarbose had IC50 values of 83.35 and 52.15 ?g/ml for fungal ?-amylase, and 92.44 and 54.84 ?g/ml for ?-glucosidase, respectively. The leaf juice had a protein content of 10.6 mg/ml and increased glucose uptake by yeast similarly to Metronidazole. Results suggest that polyphenolic compounds in the leaf juice mimic insulin in glucose utilization and inhibit ?-amylase and ?-glucosidase. Further pre-clinical assessments are needed to confirm the antidiabetic potential of this herb.
{"title":"In-Vitro antidiabetic activity of leaf juice of Mespilus Germanica L","authors":"Rajeswari Guduru, Kalyani Prakashini Ingilala","doi":"10.26452/fjphs.v4i3.626","DOIUrl":"https://doi.org/10.26452/fjphs.v4i3.626","url":null,"abstract":"Diabetes mellitus, a modern civilization disease, is marked by chronic hyperglycemia and severe complications if untreated. Type II DM, a multifactorial form, accounts for 90% of global cases. Controlling postprandial glucose is vital for preventing complications, as elevated plasma glucose is influenced by ?-amylase and ?-glucosidases. Current enzyme inhibitors like Acarbose and voglibose cause gastrointestinal side effects. This study aimed to find natural source inhibitors with fewer adverse effects using in-vitro antidiabetic assays. Mespilus germanica L. leaf juice (20-100 ?g/ml) was tested against fungal ?-amylase and ?-glucosidases from albino rat intestines. The enzymes showed dose-dependent inhibition comparable to Acarbose. LJMG and Acarbose had IC50 values of 83.35 and 52.15 ?g/ml for fungal ?-amylase, and 92.44 and 54.84 ?g/ml for ?-glucosidase, respectively. The leaf juice had a protein content of 10.6 mg/ml and increased glucose uptake by yeast similarly to Metronidazole. Results suggest that polyphenolic compounds in the leaf juice mimic insulin in glucose utilization and inhibit ?-amylase and ?-glucosidase. Further pre-clinical assessments are needed to confirm the antidiabetic potential of this herb.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":" 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141674837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Kv, Murali Mohan Kummari, Irfan Shaik, Sai Teja Narsipally, Karishma Thotlo, Ooha Chowdary Tellapati, Manasa Medisetty, Dastagiri Udayagiri
This present research aims to formulate and evaluate mouth dissolving films using Memantine as model drug to improve bioavailability and facilitate rapid onset of action to relieve vomiting and nausea. The thicknesses of the films were in the range of 0.234 mm to 0.271mm. The weights of the films were found to be in the range of ±10%. The folding endurance of the films was found to be in the range of 38± 1 to 57 ± 2. The surface pHs of all the films were neutral, as there was no color change in the litmus paper. All the films were found to be 98 to 102. The disintegration time of the prepared films ranged from 21sec to 32sec. Acceptable mechanical properties were obtained in batch F-9, and the in vitro disintegration time was below 27 sec. It has been determined that formulations F-9 were found to be satisfactory batches and were optimized for the desirable properties.
{"title":"Formulation and evaluation of mouth-dissolving films of memantine","authors":"S. Kv, Murali Mohan Kummari, Irfan Shaik, Sai Teja Narsipally, Karishma Thotlo, Ooha Chowdary Tellapati, Manasa Medisetty, Dastagiri Udayagiri","doi":"10.26452/fjphs.v4i2.612","DOIUrl":"https://doi.org/10.26452/fjphs.v4i2.612","url":null,"abstract":"This present research aims to formulate and evaluate mouth dissolving films using Memantine as model drug to improve bioavailability and facilitate rapid onset of action to relieve vomiting and nausea. The thicknesses of the films were in the range of 0.234 mm to 0.271mm. The weights of the films were found to be in the range of ±10%. The folding endurance of the films was found to be in the range of 38± 1 to 57 ± 2. The surface pHs of all the films were neutral, as there was no color change in the litmus paper. All the films were found to be 98 to 102. The disintegration time of the prepared films ranged from 21sec to 32sec. Acceptable mechanical properties were obtained in batch F-9, and the in vitro disintegration time was below 27 sec. It has been determined that formulations F-9 were found to be satisfactory batches and were optimized for the desirable properties.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"124 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141123930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：